Downregulation of peroxiredoxin II suppresses the proliferation and metastasis of gastric cancer cells

Niu,Linjun; Liu,Ang; Xu,Wei; Yang,Liang; Zhu,Wugang; Gu,Yuming

doi:10.3892/ol.2018.9208

Downregulation of peroxiredoxin II suppresses the proliferation and metastasis of gastric cancer cells

Authors:
- Linjun Niu
- Ang Liu
- Wei Xu
- Liang Yang
- Wugang Zhu
- Yuming Gu
View Affiliations

Affiliations: Department of Interventional Radiology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China
Published online on: July 25, 2018 https://doi.org/10.3892/ol.2018.9208
Pages: 4551-4560

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Peroxiredoxin (Prx) II is an imperative member of the superfamily of peroxidases. It serves an essential role in scavenging organic hydroperoxide and H2O2. It is involved in the development of various malignant tumors. In order to investigate the significance of Prx II expressions level in gastric cancer (GC), downregulation of Prx II was performed to investigate its role in the proliferation and migration of gastric adenocarcinoma cells. In GC cells and 45 GC specimens, the mRNA and protein expression levels of Prx II were determined using reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blot analysis, respectively. The Prx II expression profile in another 116 GC specimens was also detected with immunohistochemistry (IHC). The changes in the proliferation and migration of MKN45 and MGC‑803 cells folllowing transfection with small interfering RNA (siRNA) were detected by cell counting kit (CCK)‑8, western blot analysis, and Transwell migration and invasion assays. The results revealed that the expression of Prx II in GC tissues and GC cells were significantly upregulated compared with the normal control. There was a significant association between the expression level of Prx II and various factors, including tumor size, histological differentiation, the depth of invasion, the stage of tumor‑node‑metastasis (TNM) and lymph node metastasis in GC (P<0.05). Survival in patients with higher Prx II expression was significantly decreased compared with those with lower Prx II expression (P<0.01). Prx II, depth of invasion, lymph node metastasis and distant metastasis were identified as independent prognosis factors of GC (P<0.05). Knockdown of Prx II signiﬁcantly suppressed the proliferation and the migration of GC cells. These experiments revealed that Prx II promotes the development of GC, affecting the survival of patients with GC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Calcagno DQ, de Arruda Cardoso Smith M and Burbano RR: Cancer type-specific epigenetic changes: Gastric cancer. Methods Mol Biol. 1238:79–101. 2015. View Article : Google Scholar : PubMed/NCBI
3	Cheah IK, Lei F, Tang RMY, Lim KHC and Halliwell B: Ergothioneine levels in an elderly population decrease with age and incidence of cognitive decline; a risk factor for neurodegeneration? Biochem Biophys Res Commun. 478:162–167. 2016. View Article : Google Scholar : PubMed/NCBI
4	Subramanya MS, Hossain MB, Khan S, Memon B and Memon MA: Meta-analysis of D1 versus D2 gastrectomy for gastric adenocarcinoma. Islamic Countries Conferecne on Statistical Sciences. 2009.
5	Conteduca V, Sansonno D, Lauletta G, Russi S, Ingravallo G and Dammacco F: H. pylori infection and gastric cancer: State of the art (review). Int J Oncol. 42:5–18. 2013. View Article : Google Scholar : PubMed/NCBI
6	Venerito M, Vasapolli R, Rokkas T, Delchier JC and Malfertheiner P: Helicobacter pylori, gastric cancer and other gastrointestinal malignancies. Helicobacter. 22 Suppl 1:2017. View Article : Google Scholar : PubMed/NCBI
7	Sarker KK, Kabir MJ, Bhuyian AKMMU, Alam MS, Chowdhury FR, Ahad MA, Rahman MA and Rahman MM: H. pylori infection and gastric cancer in Bangladesh: A case-control study. Int J Surg Oncol (N Y). 2:e442017. View Article : Google Scholar : PubMed/NCBI
8	Grabsch HI and Tan P: Gastric cancer pathology and underlying molecular mechanisms. Dig Surg. 30:150–158. 2013. View Article : Google Scholar : PubMed/NCBI
9	Canu V, Sacconi A, Lorenzon L, Biagioni F, Lo Sardo F, Diodoro MG, Muti P, Garofalo A, Strano S, D'Errico A, et al: MiR-204 down-regulation elicited perturbation of a gene target signature common to human cholangiocarcinoma and gastric cancer. Oncotarget. 8:29540–29557. 2017. View Article : Google Scholar : PubMed/NCBI
10	Abbas M, Habib M, Naveed M, Karthik K, Dhama K, Shi M and Dingding C: The relevance of gastric cancer biomarkers in prognosis and pre- and post-chemotherapy in clinical practice. Biomed Pharmacother. 95:1082–1090. 2017. View Article : Google Scholar : PubMed/NCBI
11	Gong F, Hou G, Liu H and Zhang M: Peroxiredoxin 1 promotes tumorigenesis through regulating the activity of mTOR/p70S6K pathway in esophageal squamous cell carcinoma. Med Oncol. 32:4552015. View Article : Google Scholar : PubMed/NCBI
12	Choi H, Chang JW and Jung YK: Peroxiredoxin 6 interferes with TRAIL-induced death-inducing signaling complex formation by binding to death effector domain caspase. Cell Death Differ. 18:405–414. 2011. View Article : Google Scholar : PubMed/NCBI
13	Perkins A, Poole LB and Karplus PA: Tuning of peroxiredoxin catalysis for various physiological roles. Biochemistry. 53:7693–7705. 2014. View Article : Google Scholar : PubMed/NCBI
14	Nyström T, Yang J and Molin M: Peroxiredoxins, gerontogenes linking aging to genome instability and cancer. Genes Dev. 26:2001–2008. 2012. View Article : Google Scholar : PubMed/NCBI
15	Lehtonen ST, Svensk AM, Soini Y, Pääkkö P, Hirvikoski P, Sang WK, Säily M and Kinnula VL: Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer. 111:514–521. 2004. View Article : Google Scholar : PubMed/NCBI
16	Soini Y, Kallio JP, Hirvikoski P, Helin H, Kellokumpu-Lehtinen P, Kang SW, Tammela TL, Peltoniemi M, Martikainen PM and Kinnula VL: Oxidative/nitrosative stress and peroxiredoxin 2 are associated with grade and prognosis of human renal carcinoma. APMIS. 114:329–337. 2006. View Article : Google Scholar : PubMed/NCBI
17	Wu Y and Zhou BP: Epithelial-Mesenchymal Transition in Development and Diseases. Springer; New York: 2009
18	Petrova YI, Schecterson L and Gumbiner BM: Roles for E-cadherin cell surface regulation in cancer. Mol Biol Cell. 27:3233–3244. 2016. View Article : Google Scholar : PubMed/NCBI
19	Xian X, Huang L, Zhang B, Wu C, Cui J and Wang Z: WIN 55,212-2 inhibits the epithelial mesenchymal transition of gastric cancer cells via COX-2 signals. Cell Physiol Biochem. 39:2149–2157. 2016. View Article : Google Scholar : PubMed/NCBI
20	Lv Z, Weng X, Du C, Zhang C, Xiao H, Cai X, Ye S, Cheng J, Ding C, Xie H, et al: Downregulation of HDAC6 promotes angiogenesis in hepatocellular carcinoma cells and predicts poor prognosis in liver transplantation patients. Mol Carcinog. 55:1024–1033. 2016. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Ow SH, Chua PJ and Bay BH: Epigenetic regulation of peroxiredoxins: Implications in the pathogenesis of cancer. Exp Biol Med (Maywood). 242:140–147. 2017. View Article : Google Scholar : PubMed/NCBI
23	Rhee SG, Chae HZ and Kim K: Peroxiredoxins: A historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med. 38:1543–1552. 2005. View Article : Google Scholar : PubMed/NCBI
24	Kim H, Lee TH, Park ES, Suh JM, Park SJ, Chung HK, Kwon OY, Kim YK, Ro HK and Shong M: Role of peroxiredoxins in regulating intracellular hydrogen peroxide and hydrogen peroxide-induced apoptosis in thyroid cells. J Biol Chem. 275:18266–18270. 2000. View Article : Google Scholar : PubMed/NCBI
25	Kang SW, Chae HZ, Seo MS, Kim K, Baines IC and Rhee SG: Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J Biol Chem. 273:6297–6302. 1998. View Article : Google Scholar : PubMed/NCBI
26	Choi MH, Lee IK, Kim GW, Kim BU, Han YH, Yu DY, Park HS, Kim KY, Lee JS, Choi C, et al: Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II. Nature. 435:347–353. 2005. View Article : Google Scholar : PubMed/NCBI
27	Kwon J, Devadas S and Williams MS: T cell receptor-stimulated generation of hydrogen peroxide inhibits MEK-ERK activation and lck serine phosphorylation. Free Radic Biol Med. 35:406–417. 2003. View Article : Google Scholar : PubMed/NCBI
28	Kang DH, Lee DJ, Lee KW, Park YS, Lee JY, Lee SH, Koh YJ, Koh GY, Choi C, Yu DY, et al: Peroxiredoxin II Is an essential antioxidant enzyme that prevents the oxidative inactivation of VEGF receptor-2 in vascular endothelial cells. Mol Cell. 44:545–558. 2011. View Article : Google Scholar : PubMed/NCBI
29	Park YH, Kim SU, Kwon TH, Kim JM, Song IS, Shin HJ, Lee BK, Bang DH, Lee SJ, Lee DS, et al: Peroxiredoxin II promotes hepatic tumorigenesis through cooperation with Ras Forkhead box M1 signaling pathway. Oncogene. 35:3503–3513. 2016. View Article : Google Scholar : PubMed/NCBI
30	Karihtala P, Mäntyniemi A, Kang SW, Kinnula VL and Soini Y: Peroxiredoxins in breast carcinoma. Clin Cancer Res. 9:3418–3424. 2003.PubMed/NCBI
31	Lehtonen ST, Markkanen PM, Peltoniemi M, Kang SW and Kinnula VL: Variable overoxidation of peroxiredoxins in human lung cells in severe oxidative stress. Am J Physiol Lung Cell Mol Physiol. 288:L997–L1001. 2005. View Article : Google Scholar : PubMed/NCBI
32	Huang WJ and Zou XY: Influence of cilazapril and taurine on apoptosis of chronic hypoxic lung tissue. Chin J Patho. 1999.
33	Marengo B, Nitti M, Furfaro AL, Colla R, Ciucis CD, Marinari UM, Pronzato MA, Traverso N and Domenicotti C: Redox homeostasis and cellular antioxidant systems: crucial players in cancer growth and therapy. Oxid Med Cell Longev. 2016:62356412016. View Article : Google Scholar : PubMed/NCBI
34	Wang T, Diaz AJ and Yen Y: The role of peroxiredoxin II in chemoresistance of breast cancer cells. Breast Cancer (Dove Med Press). 6:73–80. 2014.PubMed/NCBI
35	Ward E: Cancer statistics, 2010. Ca A Cancer J Clin. 62:10–29. 2012.
36	Kim H, Yoo SB, Sun P, Jin Y, Jheon S, Lee CT and Chung JH: Alteration of the E-Cadherin/β-Catenin Complex Is an Independent Poor Prognostic Factor in Lung Adenocarcinoma. Korean J Pathol. 47:44–51. 2013. View Article : Google Scholar : PubMed/NCBI
37	Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A and Kirchner T: Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs. 179:56–65. 2005. View Article : Google Scholar : PubMed/NCBI
38	Mook OR, Frederiks WM and Van Noorden CJ: The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta. 1705:69–89. 2004.PubMed/NCBI
39	Lu W, Fu Z, Wang H, Feng J, Wei J and Guo J: Peroxiredoxin 2 knockdown by RNA interference inhibits the growth of colorectal cancer cells by downregulating Wnt/β-catenin signaling. Cancer Lett. 343:190–199. 2014. View Article : Google Scholar : PubMed/NCBI
40	Leak RK, Zhang L, Luo Y, Li P, Zhao H, Liu X, Ling F, Jia J, Chen J and Ji X: Peroxiredoxin 2 battles poly(ADP-ribose) polymerase 1- and p53-dependent prodeath pathways after ischemic injury. Stroke. 44:1124–1134. 2013. View Article : Google Scholar : PubMed/NCBI
41	Liu SL, Shi DY, Pan XH and Shen ZH: Inhibition of proliferation and expression of N-ras in hepatoma cells by antioxidation treatment. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 33:463–466. 2001.PubMed/NCBI